Literature DB >> 10207169

Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria.

J Pietz1, R Kreis, A Rupp, E Mayatepek, D Rating, C Boesch, H J Bremer.   

Abstract

Large neutral amino acids (LNAAs), including phenylalanine (Phe), compete for transport across the blood-brain barrier (BBB) via the L-type amino acid carrier. Accordingly, elevated plasma Phe impairs brain uptake of other LNAAs in patients with phenylketonuria (PKU). Direct effects of elevated brain Phe and depleted LNAAs are probably major causes for disturbed brain development and function in PKU. Competition for the carrier might conversely be put to use to lower Phe influx when the plasma concentrations of all other LNAAs are increased. This hypothesis was tested by measuring brain Phe in patients with PKU by quantitative 1H magnetic resonance spectroscopy during an oral Phe challenge with and without additional supplementation with all other LNAAs. Baseline plasma Phe was approximately 1,000 micromol/l and brain Phe was approximately 250 micromol/l in both series. Without LNAA supplementation, brain Phe increased to approximately 400 micromol/l after the oral Phe load. Electroencephalogram (EEG) spectral analysis revealed acutely disturbed brain activity. With concurrent LNAA supplementation, Phe influx was completely blocked and there was no slowing of EEG activity. These results are relevant for further characterization of the LNAA carrier and of the pathophysiology underlying brain dysfunction in PKU and for treatment of patients with PKU, as brain function might be improved by continued LNAA supplementation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10207169      PMCID: PMC408272          DOI: 10.1172/JCI5017

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  The influence of phenylalanine intake on the chemistry and behaviour of a phenyl-ketonuric child.

Authors:  H BICKEL; J GERRARD; E M HICKMANS
Journal:  Acta Paediatr       Date:  1954-01       Impact factor: 2.299

2.  Nutritional value of essential amino acids in the treatment of adults with phenylketonuria.

Authors:  H Dotremont; B François; M Diels; P Gillis
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

3.  Neuropsychology of early-treated phenylketonuria: specific executive function deficits.

Authors:  M C Welsh; B F Pennington; S Ozonoff; B Rouse; E R McCabe
Journal:  Child Dev       Date:  1990-12

4.  Valine, isoleucine, and leucine. A new treatment for phenylketonuria.

Authors:  H K Berry; R L Brunner; M M Hunt; P P White
Journal:  Am J Dis Child       Date:  1990-05

5.  Versatile frequency domain fitting using time domain models and prior knowledge.

Authors:  J Slotboom; C Boesch; R Kreis
Journal:  Magn Reson Med       Date:  1998-06       Impact factor: 4.668

6.  Utilisation of amino acid mixtures in adolescents with phenylketonuria.

Authors:  E Mönch; M E Herrmann; H Brösicke; A Schöffer; M Keller
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

7.  In vivo measurement of phenylalanine in human brain by proton nuclear magnetic resonance spectroscopy.

Authors:  E J Novotny; M J Avison; N Herschkowitz; O A Petroff; J W Prichard; M R Seashore; D L Rothman
Journal:  Pediatr Res       Date:  1995-02       Impact factor: 3.756

8.  Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man.

Authors:  W Krause; M Halminski; L McDonald; P Dembure; R Salvo; D Freides; L Elsas
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

9.  Identification and quantitation of phenylalanine in the brain of patients with phenylketonuria by means of localized in vivo 1H magnetic-resonance spectroscopy.

Authors:  R Kreis; J Pietz; J Penzien; N Herschkowitz; C Boesch
Journal:  J Magn Reson B       Date:  1995-06

10.  Inhibition of neutral amino acid transport across the human blood-brain barrier by phenylalanine.

Authors:  B L Shulkin; A L Betz; R A Koeppe; B W Agranoff
Journal:  J Neurochem       Date:  1995-03       Impact factor: 5.372

View more
  76 in total

1.  A comparative analysis of biclustering algorithms for gene expression data.

Authors:  Kemal Eren; Mehmet Deveci; Onur Küçüktunç; Ümit V Çatalyürek
Journal:  Brief Bioinform       Date:  2012-07-06       Impact factor: 11.622

Review 2.  Phenylketonuria: a 21st century perspective.

Authors:  Francjan J van Spronsen
Journal:  Nat Rev Endocrinol       Date:  2010-09       Impact factor: 43.330

3.  Characterization of 2-(methylamino)alkanoic acid capacity to restrict blood-brain phenylalanine transport in Pah enu2 mice: preliminary findings.

Authors:  Kara R Vogel; Erland Arning; Brandi L Wasek; Teodoro Bottiglieri; K Michael Gibson
Journal:  Mol Genet Metab       Date:  2013-08-15       Impact factor: 4.797

4.  Tackling frontal lobe-related functions in PKU through functional brain imaging: a Stroop task in adult patients.

Authors:  Benedikt Sundermann; Bettina Pfleiderer; Harald E Möller; Wolfram Schwindt; Josef Weglage; Jöran Lepsien; Reinhold Feldmann
Journal:  J Inherit Metab Dis       Date:  2011-04-14       Impact factor: 4.982

Review 5.  Nutritional management of PKU with glycomacropeptide from cheese whey.

Authors:  D M Ney; S T Gleason; S C van Calcar; E L MacLeod; K L Nelson; M R Etzel; G M Rice; J A Wolff
Journal:  J Inherit Metab Dis       Date:  2008-10-29       Impact factor: 4.982

6.  Phenylketonuria: an inborn error of phenylalanine metabolism.

Authors:  Robin A Williams; Cyril D S Mamotte; John R Burnett
Journal:  Clin Biochem Rev       Date:  2008-02

7.  Developmental timing of exposure to elevated levels of phenylalanine is associated with ADHD symptom expression.

Authors:  Kevin M Antshel; Susan E Waisbren
Journal:  J Abnorm Child Psychol       Date:  2003-12

Review 8.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

Review 9.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016

Review 10.  Large neutral amino acids in the treatment of PKU: from theory to practice.

Authors:  Francjan J van Spronsen; Martijn J de Groot; Marieke Hoeksma; Dirk-Jan Reijngoud; Margreet van Rijn
Journal:  J Inherit Metab Dis       Date:  2010-10-26       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.